^9^0Y Ibritumomab Tiuxetan (Y2B8, Zevalin®) Radioimmunotherap (RIT) Is Highly Effective for Relapsed or Refractory Indolent B-Cell Non-Hodgkin's Lymphoma (B-NHL) Pretreated with Rituximab-Containing Chemotherapy (R-Chemo): Japanese Multicenter Phase II Study. (Poster # 945-II) (English)
- New search for: Ogura, M.
- New search for: Morishima, Y.
- New search for: Watanabe, T.
- New search for: Hotta, T.
- New search for: Ishizawa, K.
- New search for: Itoh, K.
- New search for: Okamoto, S.
- New search for: Taniwaki, M.
- New search for: Endo, K.
- New search for: Tobinai, K.
- New search for: American Society of Hematology
- New search for: Ogura, M.
- New search for: Morishima, Y.
- New search for: Watanabe, T.
- New search for: Hotta, T.
- New search for: Ishizawa, K.
- New search for: Itoh, K.
- New search for: Okamoto, S.
- New search for: Taniwaki, M.
- New search for: Endo, K.
- New search for: Tobinai, K.
- New search for: American Society of Hematology
In:
American Society of Hematology
11
;
2767
;
2006
-
ISSN:
- Conference paper / Print
-
Title:^9^0Y Ibritumomab Tiuxetan (Y2B8, Zevalin®) Radioimmunotherap (RIT) Is Highly Effective for Relapsed or Refractory Indolent B-Cell Non-Hodgkin's Lymphoma (B-NHL) Pretreated with Rituximab-Containing Chemotherapy (R-Chemo): Japanese Multicenter Phase II Study. (Poster # 945-II)
-
Contributors:Ogura, M. ( author ) / Morishima, Y. ( author ) / Watanabe, T. ( author ) / Hotta, T. ( author ) / Ishizawa, K. ( author ) / Itoh, K. ( author ) / Okamoto, S. ( author ) / Taniwaki, M. ( author ) / Endo, K. ( author ) / Tobinai, K. ( author )
-
Conference:48th:; ANNUAL MEETING, American Society of Hematology ; 2006 ; Orlando, FL
-
Published in:American Society of Hematology , 11 ; 2767BLOOD -NEW YORK- ; 108, 11 ; 2767
-
Publisher:
- New search for: American Society of Hematology,
-
Publication date:2006-01-01
-
Size:2767 pages
-
ISSN:
-
Type of media:Conference paper
-
Type of material:Print
-
Language:English
-
Keywords:
-
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.